Non-insulin oral drug(s)-Amaryl (Glimepiride) Posts on Medivizor
Navigation Menu

Non-insulin oral drug(s)-Amaryl (Glimepiride) Posts on Medivizor

Looking for patients with type 2 diabetes to test a new treatment tirzepatide

Posted by on Feb 27, 2019 in Diabetes mellitus | 0 comments

In a nutshell This trial is examining the effectiveness of tirzepatide compared to insulin glargine in patients with type 2 diabetes who are also at high risk for heart disease. The main outcome to be measured will be a change in HbA1c (a blood test that measures average blood sugar levels in the past 3 months) over 52 weeks. The details In type 2...

Read More

Can dipeptidyl peptidase-4 inhibitors reduce the risk of autoimmune disease?

Can dipeptidyl peptidase-4 inhibitors reduce the risk of autoimmune disease?

Posted by on Jul 21, 2014 in Diabetes mellitus | 0 comments

In a nutshell The authors evaluated the risk of autoimmune disease development in patients starting a dipeptidyl peptidase inhibitor for type 2 diabetes. Some background Dipeptidyl peptidase-4 (DPP4) is a protein that plays a major role in glucose metabolism. DPP4-inhbitors such as linagliptin (Tradjenta), saxagliptin (Onglyza) and sitagliptin...

Read More

Addition of insulin glargine to combination therapy with oral anti-diabetic drugs: a promising therapeutic option for type 2 diabetes

Addition of insulin glargine to combination therapy with oral anti-diabetic drugs: a promising therapeutic option for type 2 diabetes

Posted by on May 6, 2014 in Diabetes mellitus | 0 comments

In a nutshell This study compared the effects of adding insulin glargine treatment  to metformin (Glucophage), glimepiride (Amaryl) or their combination in patients with uncontrolled type 2 diabetes mellitus. Some background Hyperglycemia (high blood glucose) in type 2 diabetes mellitus arises from a combination...

Read More